---
schema_version: "secwatch.filing_event.v1"
accession: "0001846253-23-000064"
form_type: "8-K"
ticker: "OABI"
cik: "0001846253"
company_name: "OmniAb, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:51:46.046423+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# OmniAb Q1 2023 revenue $16.9M, net loss $6.1M; 301 active partner programs

## Summary
- Revenue $16.9M, up from $9.6M YoY, driven by $10.0M milestone from TECVAYLI EU commercial sale.
- Net loss $6.1M ($0.06/share) vs $6.3M ($0.08/share) YoY; cash & investments $113.6M.
- 301 active programs, 27 in clinical/commercial; new license with Neurocrine Biosciences post-quarter.
- Introduced OmniDeep in silico platform; Seagen's SGN-BB228 entered Phase 1 for melanoma.
- Immunovant expects Phase 2 Graves' disease results H2 2023; CStone sBLA for sugemalimab in ESCC.

## SEC filing metadata
- accession: 0001846253-23-000064
- form_type: 8-K
- ticker: OABI
- cik: 0001846253
- company_name: OmniAb, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1846253/000184625323000064/0001846253-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1846253/000184625323000064/lgnd-20230511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001846253-23-000064
- JSON: https://secwatch.observer/filing/0001846253-23-000064.json
- Plain text: https://secwatch.observer/filing/0001846253-23-000064.txt

## Key facts
- Earnings Releases
  OmniAb, Inc. reported the three months ended March 31, 2023 results: revenue $16.9 million, net income $6.1 million, EPS $0.06 per share.
  - Period: the three months ended March 31, 2023
  - Revenue: $16.9 million
  - Net income: $6.1 million
  - EPS: $0.06 per share
  - Result: reported results
  source text: Revenue for the first quarter of 2023 was $16.9 million, compared with $9.6 million for the same period in 2022, with the increase primarily due to the recognition of a $10.0 million milestone payment related to the first commercial sale of TECVAYLI® (teclistamab) in the European Union. Research and development expense was $13.8 million for the first quarter of 2023, compared with $10.8 million for the same period in 2022, with the increase primarily due to investments in facilities, headcount and technology innovation. General and administrative expense was $8.2 million for the first quarter of 2023, compared with $4.1 million for the same period in 2022, with the increase primarily due to higher headcount and other expenses related to being an independent publicly traded company. Net loss for the first quarter of 2023 was $6.1 million, or $0.06 per share, compared with a net loss of $6.3 million, or $0.08 per share, for the same period in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1846253/000184625323000064/0001846253-23-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.